Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease

被引:47
作者
Dieplinger, Benjamin
Lingenhel, Arno
Baumgartner, Nadja
Poelz, Werner
Dieplinger, Hans
Haltmayer, Meinhard
Kronenberg, Florian
Mueller, Thomas
机构
[1] Koventhosp Barmherzige Brueder, Dept Lab Med, A-4020 Linz, Austria
[2] Innsbruck Med Univ, Dept Med Genet Mol & Clin Pharmacol, Div Genet Epidemiol, Innsbruck, Austria
[3] Univ Linz, Dept Appl Syst Sci & Stat, A-4040 Linz, Austria
关键词
D O I
10.1373/clinchem.2007.088013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Increased concentrations of lipoprotein(a) [Lp(a)] have been considered a genetically determined risk factor for coronary artery and cerebrovascular disease. Only 2 small and conflicting studies have investigated the possibility of an association of peripheral arterial disease (PAD) with high serum Lp(a) concentrations and low molecular weight (LMW) phenotypes of apolipoprotein(a) [apo(a)]. Methods: We measured serum concentrations of Lp(a) and apo(a) phenotypes in 213 patients with symptomatic PAD and 213 controls matched for sex, age (within 2 years), and presence of diabetes. Results: Patients with PAD showed significantly higher median serum concentrations of Lp(a) (76 vs 47 mg/L; P = 0.003) and a higher frequency of LMW apo(a) phenotypes (41% vs 26%; P = 0.002) than controls. After adjustment for several potential confounders, increased Lp(a) concentrations (>195 mg/L, i.e., 75th percentile of the entire study sample) and LMW apo(a) phenotypes were significant predictors of PAD, with odds ratios of 3.73 (95% CI 2.08-6.67; P <0.001) and 2.21 (95% CI 1.33-3.67; P = 0.002), respectively. Conclusions: In this study sample, both increased serum concentrations of Lp(a) and the presence of LMW apo(a) phenotypes were associated with the presence of symptomatic PAD independent of traditional and nontraditional cardiovascular risk factors. Because PAD is considered an indicator of systemic atherosclerotic disease, our results suggest a possible role of Lp(a) as a genetically determined marker for systemic atherosclerosis. (c) 2007 American Association for Clinical Chemistry.
引用
收藏
页码:1298 / 1305
页数:8
相关论文
共 40 条
[1]   Critical issues in peripheral arterial disease detection and management - A call to action [J].
Belch, JJF ;
Topol, EJ ;
Agnelli, G ;
Bertrand, M ;
Califf, RM ;
Clement, DL ;
Creager, MA ;
Easton, JD ;
Gavin, JR ;
Greenland, P ;
Hankey, G ;
Hanrath, P ;
Hirsch, AT ;
Meyer, J ;
Smith, SC ;
Sullivan, F ;
Weber, MA .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (08) :884-892
[2]   Pregnancy-associated plasma protein-A: Do specific markers of vascular or plaque activation exist, and do we really need them? [J].
Biasucci, Luigi M. ;
Rizzello, Vittoria .
CLINICAL CHEMISTRY, 2006, 52 (06) :913-914
[3]   APOLIPOPROTEIN(A) GENE ACCOUNTS FOR GREATER THAN 90-PERCENT OF THE VARIATION IN PLASMA LIPOPROTEIN(A) CONCENTRATIONS [J].
BOERWINKLE, E ;
LEFFERT, CC ;
LIN, JP ;
LACKNER, C ;
CHIESA, G ;
HOBBS, HH .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (01) :52-60
[4]   Lipoprotein(a) and coronary heart disease - Meta-analysis of prospective studies [J].
Danesh, J ;
Collins, R ;
Peto, R .
CIRCULATION, 2000, 102 (10) :1082-1085
[5]   Lipoprotein(a) and inflammation in human coronary atheroma: Association with the severity of clinical presentation [J].
Dangas, G ;
Mehran, R ;
Harpel, PC ;
Sharma, SK ;
Marcovina, SM ;
Dube, G ;
Ambrose, JA ;
Fallon, JT .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (07) :2035-2042
[6]  
Danik JS, 2006, JAMA-J AM MED ASSOC, V296, P1363, DOI 10.1001/jama.296.11.1363
[7]  
DERIJKE YB, 1992, J LIPID RES, V33, P1315
[8]  
DIEPLINGER H, 1995, J LIPID RES, V36, P813
[9]   ELEVATED PLASMA-CONCENTRATIONS OF LIPOPROTEIN(A) IN PATIENTS WITH END-STAGE RENAL-DISEASE ARE NOT RELATED TO THE SIZE POLYMORPHISM OF APOLIPOPROTEIN(A) [J].
DIEPLINGER, H ;
LACKNER, C ;
KRONENBERG, F ;
SANDHOLZER, C ;
LHOTTA, K ;
HOPPICHLER, F ;
GRAF, H ;
KONIG, P .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (02) :397-401
[10]   LIPOPROTEIN(A) BINDS TO HUMAN PLATELETS AND ATTENUATES PLASMINOGEN BINDING AND ACTIVATION [J].
EZRATTY, A ;
SIMON, DI ;
LOSCALZO, J .
BIOCHEMISTRY, 1993, 32 (17) :4628-4633